Please select the option that best describes you:
Would you consider enfortumab vedotin + pembrolizumab prior to surgery for a patient with urothelial carcinoma with regional nodes who is not eligible for neoadjuvant cisplatin?
This would be for the "locally advanced unresectable" indication. Consider an older patient who is not eligible for NAC nor TMT due to nodal disease and patient related factors.
Answer from: Medical Oncologist at Community Practice
The appropriate management for LN+ bladder cancer is not clear, and whether or not to use EV+pembrolizumab in this setting is also without significant data. Clinically and practically, there are so many gray areas in this question that the best path is at best charcoal-colored. Generally, systemic t...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
We actually have a trial open for these patients! EV-ECLIPSE - multicenter trial coordinated from MSKCC and open at UTSW in Dallas -- we are looking to fill out the cohort and learn from these patients! Absolutely think there is activity for EV-pembro not only in the LNs but also in the primary tumo...